奇富科技(03660) - 2025 - 中期财报

2025-08-14 22:41
[Performance Overview & Management Commentary](index=2&type=section&id=Performance%20Overview%20%26%20Management%20Commentary) [Q2 2025 Business Highlights](index=2&type=section&id=Q2%202025%20Business%20Highlights) In Q2 2025, the company achieved year-over-year growth in user base and outstanding loan balance, with 41.4% of total facilitated loans under light-capital models and a 90-day+ delinquency rate of 1.97% Q2 2025 Key Operating Metrics | Metric | Q2 2025 | YoY Change | QoQ Change | | :--- | :--- | :--- | :--- | | Total Facilitated and Originated Loan Volume | RMB 84.61 billion | +16.1% | -4.8% | | - Light-Capital/ICE/Tech Solution Share | 41.4% | - | - | | Total Outstanding Loan Balance at Period End | RMB 140.08 billion | +13.4% | -0.1% | | - Light-Capital/ICE/Tech Solution Share | Approx. 51% | - | - | | Cumulative Approved Credit Line Users | 60.2 million | +12.3% | - | | Cumulative Successful Borrower Withdrawals | 36.8 million | +14.9% | - | | 90-Day+ Delinquency Rate | 1.97% | - | - | [Q2 2025 Financial Highlights](index=3&type=section&id=Q2%202025%20Financial%20Highlights) The company achieved robust financial performance in Q2 2025, with total net revenue reaching **RMB 5.22 billion** and Non-GAAP net profit at **RMB 1.85 billion**, demonstrating sustained profitability Q2 2025 Key Financial Data | Metric | Amount (RMB) | Amount (USD) | | :--- | :--- | :--- | | Total Net Revenue | 5.216 billion | 0.728 billion | | Net Profit | 1.731 billion | 0.242 billion | | Non-GAAP Net Profit | 1.849 billion | 0.258 billion | | Diluted Net Earnings Per ADS | 12.76 | 1.78 | | Diluted Non-GAAP Net Earnings Per ADS | 13.63 | 1.90 | [Management Commentary](index=3&type=section&id=Management%20Commentary) Management highlighted the company's resilient operations amidst macroeconomic uncertainties and regulatory changes, achieved by tightening risk controls, optimizing business structure with **51%** light-asset model share, and diversifying customer acquisition channels, while prudently increasing provisions to near historical highs - CEO Wu Haisheng noted that in response to economic uncertainties and regulatory changes, the company proactively tightened risk control standards and adjusted its business structure, with the outstanding loan balance from light-asset models, ICE, and comprehensive technology solutions reaching approximately **51%**[7](index=7&type=chunk) - CFO Xu Zuoli emphasized that despite the volatile macroeconomic environment, the company achieved robust financial performance and prudently assessed risks, with new provisions in Q2 approaching historical highs[7](index=7&type=chunk) - CRO Zheng Yan added that influenced by macroeconomic challenges, overall market risk levels fluctuated, with the first-day delinquency rate reaching **5.1%**, prompting the company to tighten risk controls and potentially implement further measures to mitigate potential risks[7](index=7&type=chunk) [Financial Performance Analysis](index=4&type=section&id=Financial%20Performance%20Analysis) [Operating Results](index=4&type=section&id=Operating%20Results) In Q2 2025, total net revenue grew **25.4%** to **RMB 5.22 billion**, driven by credit-driven and platform services, while operating costs and expenses significantly increased **41.6%** to **RMB 3.08 billion**, resulting in operating income of **RMB 2.14 billion**, up **7.6%** year-over-year [Net Revenue](index=4&type=section&id=Net%20Revenue) Total net revenue reached **RMB 5.22 billion**, a **25.4%** year-over-year increase, with credit-driven service net revenue at **RMB 3.57 billion** (up **22.4%**) and platform service net revenue at **RMB 1.65 billion** (up **32.3%**), driven by increased financing income and referral service fees respectively Q2 2025 Net Revenue Composition (RMB million) | Revenue Item | Q2 2025 | Q2 2024 | YoY Change | | :--- | :--- | :--- | :--- | | **Total Net Revenue** | **5,215.9** | **4,160.1** | **+25.4%** | | **Credit-Driven Service Net Revenue** | **3,565.5** | **2,912.2** | **+22.4%** | | - Financing Income | 2,205.0 | 1,690.1 | +30.5% | | - Release of Guarantee Liabilities Income | 805.3 | 972.6 | -17.2% | | **Platform Service Net Revenue** | **1,650.3** | **1,247.9** | **+32.3%** | | - Loan Facilitation and Service Fees - Light-Capital | 326.8 | 524.4 | -37.7% | | - Referral Service Fees | 986.4 | 623.5 | +58.2% | [Operating Costs and Expenses](index=5&type=section&id=Operating%20Costs%20and%20Expenses) Total operating costs and expenses increased **41.6%** to **RMB 3.08 billion**, primarily driven by a rise in sales and marketing expenses to **RMB 663 million** due to increased investment in embedded finance channels and information flow advertising, and a significant increase in contingent liability provisions to **RMB 398 million** due to higher heavy-capital loan volumes and risk assessment adjustments Q2 2025 Operating Costs and Expenses Composition (RMB million) | Cost Item | Q2 2025 | Q2 2024 | YoY Change Reason | | :--- | :--- | :--- | :--- | | **Total** | **3,079.7** | **2,175.1** | **-** | | Facilitation, Origination and Servicing Expenses | 781.0 | 722.2 | Increase in total loan volume | | Sales and Marketing Expenses | 662.7 | 366.4 | Increased investment in embedded finance channels and information flow advertising | | Provision for Loans Receivable | 773.8 | 849.5 | Reversal of prior provisions, partially offset by increase in on-balance sheet loans | | Provision for Contingent Liabilities | 397.6 | (213.3) | Increase in heavy-capital loan facilitation volume and risk assessment adjustments | [Profitability and EPS](index=6&type=section&id=Profitability%20and%20EPS) In Q2 2025, the company achieved operating income of **RMB 2.14 billion**, net profit of **RMB 1.73 billion** (up **25.7%** YoY), and Non-GAAP net profit of **RMB 1.85 billion** (up **30.8%** YoY), with diluted net earnings per ADS at **RMB 12.76** Q2 2025 Profitability Metrics (RMB million) | Metric | Q2 2025 | Q2 2024 | YoY Change | | :--- | :--- | :--- | :--- | | Operating Income | 2,136.2 | 1,985.0 | +7.6% | | Non-GAAP Operating Income | 2,254.7 | 2,021.9 | +11.5% | | Net Profit | 1,730.5 | 1,376.5 | +25.7% | | Non-GAAP Net Profit | 1,849.0 | 1,413.4 | +30.8% | | Diluted Net Earnings Per ADS (RMB) | 12.76 | 8.92 | +43.0% | [Asset Quality](index=7&type=section&id=Asset%20Quality) The report presents asset quality performance of facilitated loans across different periods through 30-day+ and 180-day+ delinquency rate charts (Vintage Curves), which are key tools for assessing credit business risk trends - The report provides quarterly historical loan 30-day+ and 180-day+ delinquency rate charts to track the asset quality performance of loans originated in different periods[22](index=22&type=chunk)[23](index=23&type=chunk)[26](index=26&type=chunk) [Shareholder Returns & Business Outlook](index=7&type=section&id=Shareholder%20Returns%20%26%20Business%20Outlook) [Dividends and Share Repurchase](index=7&type=section&id=Dividends%20and%20Share%20Repurchase) The company declared a H1 2025 dividend of **USD 0.76** per ADS and actively executed its share repurchase program, having repurchased approximately **USD 277 million** in ADS under the 2025 plan as of August 14, 2025 - The Board approved a H1 2025 dividend of **USD 0.38** per Class A ordinary share or **USD 0.76** per ADS, with the record date set for September 8, 2025[25](index=25&type=chunk) - As of August 14, 2025, the company repurchased approximately **7.1 million** ADS at an average price of **USD 38.9/ADS**, totaling approximately **USD 277 million**, under its **USD 450 million** 2025 share repurchase program[27](index=27&type=chunk) [Business Outlook](index=8&type=section&id=Business%20Outlook) Given ongoing macroeconomic uncertainties, the company maintains a cautious outlook for Q3 2025, projecting net profit between **RMB 1.52 billion** and **RMB 1.72 billion**, and Non-GAAP net profit between **RMB 1.60 billion** and **RMB 1.80 billion**, representing a **2% to 13%** year-over-year decrease Q3 2025 Performance Guidance | Metric | Forecast Range (RMB billion) | YoY Change | | :--- | :--- | :--- | | Net Profit | 1.52 - 1.72 billion | -13% to -2% | | Non-GAAP Net Profit | 1.60 - 1.80 billion | - | [Financial Statements](index=11&type=section&id=Financial%20Statements) [Unaudited Condensed Consolidated Balance Sheets](index=11&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets reached **RMB 59.75 billion**, up **24.1%** from year-end 2024, primarily driven by increased net loans receivable, with total liabilities at **RMB 35.65 billion** and total equity at **RMB 24.11 billion**, indicating a stable balance sheet structure Key Balance Sheet Items (As of June 30, 2025) | Item | Amount (RMB billion) | | :--- | :--- | | **Total Assets** | **59.75** | | Cash, Cash Equivalents and Restricted Cash | 8.21 | | Net Loans Receivable (Current + Non-current) | 37.43 | | **Total Liabilities** | **35.65** | | Amounts Due to Consolidated Trust Investors | 20.00 | | **Total Equity** | **24.11** | [Unaudited Condensed Consolidated Statements of Operations](index=12&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) This statement details the company's revenue, costs, and profit composition for Q2 and H1 2025, showing Q2 net revenue of **RMB 5.22 billion**, operating income of **RMB 2.14 billion**, and net profit of **RMB 1.73 billion** Q2 2025 Income Statement Overview (RMB million) | Item | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Total Net Revenue | 5,215.9 | 4,160.1 | | Total Operating Costs and Expenses | 3,079.7 | 2,175.1 | | Operating Income | 2,136.2 | 1,985.0 | | Net Profit | 1,730.5 | 1,376.5 | [Unaudited Condensed Consolidated Statements of Cash Flows](index=13&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) In Q2 2025, the company generated **RMB 2.62 billion** in net cash from operating activities, indicating strong core business cash generation, while net cash used in investing activities was **RMB 8.19 billion**, and net cash from financing activities was **RMB 2.00 billion** Q2 2025 Cash Flow Statement Overview (RMB million) | Item | Q2 2025 | | :--- | :--- | | Net Cash from Operating Activities | 2,622.0 | | Net Cash Used in Investing Activities | (8,191.1) | | Net Cash from Financing Activities | 1,995.6 | | Cash, Cash Equivalents and Restricted Cash at Period End | 8,212.4 | [GAAP to IFRS Reconciliation](index=17&type=section&id=GAAP%20to%20IFRS%20Reconciliation) [Reconciliation Explanation and Results](index=17&type=section&id=Reconciliation%20Explanation%20and%20Results) This section provides a quantitative reconciliation of financial statements prepared under US GAAP to IFRS, as required by HKEX, showing H1 2025 net profit of **RMB 3.52 billion** under IFRS, slightly lower than **RMB 3.53 billion** under US GAAP - The company's directors prepared interim financial statements under US GAAP and disclosed a reconciliation of differences with International Financial Reporting Standards (IFRS)[51](index=51&type=chunk) - Deloitte Touche Tohmatsu has performed a limited assurance engagement on this reconciliation statement and found no material issues[54](index=54&type=chunk)[55](index=55&type=chunk) [Notes on Key Accounting Differences](index=24&type=section&id=Notes%20on%20Key%20Accounting%20Differences) The report details five key accounting differences between US GAAP and IFRS: expected credit loss recognition (CECL vs. IFRS 9 three-stage model), effective interest rate calculation, share-based payment attribution, financial guarantee accounting, and convertible preferred note measurement - Expected Credit Losses: US GAAP uses the CECL model to recognize lifetime expected losses at inception, while IFRS 9 employs a three-stage model, recognizing lifetime losses only when credit risk significantly increases[62](index=62&type=chunk) - Effective Interest Rate: US GAAP calculates based on contractual cash flows, whereas IFRS uses estimated cash flows[63](index=63&type=chunk) - Financial Guarantees: US GAAP recognizes standby and contingent guarantee liabilities using the gross method, while IFRS recognizes revenue based on premiums received and measures liabilities at the higher of loss allowance or initial recognition amount[63](index=63&type=chunk) - Convertible Preferred Notes: Under US GAAP, they are measured as liabilities, while under IFRS, they are designated as fair value through profit or loss[63](index=63&type=chunk)
盛业(06069) - 2025 - 中期业绩
2025-08-14 22:03
[Performance Highlights](index=1&type=section&id=%E6%A5%AD%E7%B8%BE%E6%91%98%E8%A6%81) H1 2025 saw significant growth in platform technology service revenue and net profit, driven by platformization and AI applications Key Performance Indicators for H1 2025 | Indicator | H1 2025 | H1 2024 | YoY Change | | :--- | :--- | :--- | :--- | | Platform Technology Service Revenue | 210.6 million RMB | 153.8 million RMB | +37.0% | | Profit After Tax | 203.0 million RMB | 165.1 million RMB | +22.9% | | Total Cumulative Platform Customers | >19,100 | >16,700 | +14.4% | | Cumulative Supply Chain Assets Processed | ~278.0 billion RMB | ~216.0 billion RMB | +28.7% | - The platformization strategy continues to deepen, with funding partners increasing from 138 to 181, a **31.2% year-on-year growth**. Small and medium-sized enterprise (SME) clients account for **over 97%**[2](index=2&type=chunk) - Technology service revenue reached approximately **52.0% of total operating revenue**, a significant increase from **35.3% in the prior year**, becoming a core growth driver[2](index=2&type=chunk) - First-time AI information service revenue exceeded **400,000 RMB**, generated by AI Agents assisting clients in order acquisition, marking initial success in AI commercialization[2](index=2&type=chunk) [Management Discussion and Analysis](index=2&type=section&id=%E7%AE%A1%E7%90%86%E5%B1%A4%E8%A8%8E%E8%AB%96%E8%88%87%E5%88%86%E6%9E%90) This section analyzes the company's operational performance, financial results, and future outlook [Business Overview](index=2&type=section&id=%E6%A5%AD%E5%8B%99%E6%A6%82%E8%A6%BD) The 'AI+Industrial Supply Chain' firm saw **22.9%** net profit growth in H1 2025, fueled by platform tech services and global expansion Key Financial and Operating Data for H1 2025 | Indicator | H1 2025 | YoY Change | | :--- | :--- | :--- | | Net Profit | 203.0 million RMB | +22.9% | | Operating Revenue and Income | 405.1 million RMB | -7.1% | | Share of Results of Associates | 79.0 million RMB | +94.1% | | Total Cumulative Platform Customers | >19,100 | +14.4% | | Cumulative Supply Chain Assets Processed | ~278.0 billion RMB | +28.7% | | Platform Technology Service Revenue | 210.6 million RMB | +37.0% | - The company continues to advance its 'asset-light' operating model, with platform technology service revenue exceeding **50% of total revenue**, becoming the primary growth driver[5](index=5&type=chunk) - Initial commercialization of AI technology achieved, with AI Agent-assisted order acquisition generating over **400,000 RMB** in AI information service revenue[5](index=5&type=chunk) - Actively expanding into strategic emerging industries, with e-commerce funding facilitation growing nearly **8 times year-on-year**; partnered with Standard Robots to enter the robotics sector; introduced XtalPi and Jiaoge Pengyou as strategic investors to enhance AI R&D and live e-commerce capabilities[7](index=7&type=chunk) - The company committed to a three-year dividend payout ratio of no less than **90% until 2026**, with total dividends for 2025 expected to be approximately **950 million RMB**[6](index=6&type=chunk) [Business Outlook and Prospects](index=5&type=section&id=%E6%A5%AD%E5%8B%99%E5%B1%95%E6%9C%9B%E8%88%87%E5%89%8D%E6%99%AF) The company established its Singapore HQ to expand internationally, exploring Web3.0 and stablecoins for global supply chain efficiency - Established Singapore International Headquarters to expand international markets and explore innovative applications of Web3.0 and stablecoins[8](index=8&type=chunk) - Invested in a top SHEIN supplier to support the construction of flexible smart factories overseas and promote the globalization of China's apparel industry; completed the first international working capital facilitation business with the largest integrated logistics enterprise in the Philippines[9](index=9&type=chunk) - Plans to explore the compliant application of stablecoins in international supply chain working capital services, leveraging their 'payment-as-settlement' feature to reduce payment costs to **0.1%**, mitigate exchange rate risks, and enhance capital efficiency[10](index=10&type=chunk) [Financial Review](index=6&type=section&id=%E8%B2%A1%E5%8B%99%E5%9B%9E%E9%A1%A7) H1 2025 saw structural financial optimization: **7.1%** revenue decrease, **22.9%** net profit growth, driven by platform tech services and reduced financing costs [Financial Summary](index=6&type=section&id=%E8%B2%A1%E5%8B%99%E6%A6%82%E8%A6%81) Operating revenue decreased **7.1%**, but net profit rose **22.9%**, with EPS increasing from **16 to 20 RMB cents** Financial Summary (Six Months Ended June 30) | Indicator (RMB thousands) | 2025 | 2024 | YoY Change | | :--- | :--- | :--- | :--- | | **Operating Revenue and Income** | **405,090** | **436,050** | **(7.1%)** | | — Platform Technology Service Revenue | 210,641 | 153,779 | 37.0% | | — Digital Financial Solutions Revenue | 194,021 | 275,038 | (29.5%) | | Financing Costs | 122,599 | 185,414 | (33.9%) | | Share of Results of Associates | 78,994 | 40,702 | 94.1% | | **Net Profit** | **202,959** | **165,126** | **22.9%** | | Earnings Per Share (RMB cents) | 20 RMB cents | 16 RMB cents | 25.0% | [Operating Revenue and Income](index=6&type=section&id=%E4%B8%BB%E7%87%9F%E6%A5%AD%E5%8B%99%E6%94%B6%E5%85%A5%E5%8F%8A%E6%94%B6%E7%9B%8A) Total revenue decreased **7.1%** due to the asset-light strategy, offset by significant growth in platform technology service revenue - Platform technology service revenue increased from **154 million RMB** to **211 million RMB**, a **37.0% year-on-year growth**, primarily due to strengthened platform ecosystem connections and technological capabilities, serving more SME clients[14](index=14&type=chunk) - Digital financial solutions revenue decreased from **275 million RMB** to **194 million RMB**, a **29.5% year-on-year reduction**, reflecting the company's asset-light strategy of reducing proprietary capital investment and shifting towards platform facilitation[15](index=15&type=chunk) [Share of Results of Associates](index=8&type=section&id=%E6%87%89%E4%BD%94%E8%81%AF%E7%87%9F%E5%85%AC%E5%8F%B8%E6%A5%AD%E7%B8%BE) Share of results of associates significantly increased by **94.1%** to **79.0 million RMB**, a key outcome of platformization - Share of results of associates significantly increased from **40.7 million RMB** in the prior year to **79.0 million RMB**, a **94.1% year-on-year increase**[18](index=18&type=chunk) [Expenses](index=8&type=section&id=%E6%94%AF%E5%87%BA) Total operating expenses increased by **13.8%** to **123 million RMB**, with the cost-to-revenue ratio rising to **30.4%** Operating Expense Details (Six Months Ended June 30) | Expense Item (RMB thousands) | 2025 | 2024 | YoY Change | | :--- | :--- | :--- | :--- | | Staff Costs | 73,708 | 69,127 | 6.6% | | Depreciation and Amortization | 19,057 | 15,003 | 27.0% | | Other Operating Expenses | 30,393 | 24,108 | 26.1% | | **Total** | **123,158** | **108,238** | **13.8%** | [Capital Structure, Liquidity, Financial Resources, and Leverage](index=13&type=section&id=%E8%B3%87%E6%9C%AC%E6%9E%B6%E6%A7%8B%E3%80%81%E6%B5%81%E5%8B%95%E6%80%A7%E3%80%81%E8%B2%A1%E5%8B%99%E8%B3%87%E6%BA%90%E5%8F%8A%E6%A3%BF%E6%A1%BF) As of June 30, 2025, cash and cash equivalents were **713 million RMB**, operating cash inflow was **3.56 billion RMB**, and leverage ratio increased from **1.58 to 1.95** Key Capital Structure Indicators | Indicator | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and Cash Equivalents | 712.8 million RMB | 515.6 million RMB | | Interest-bearing Borrowings and Related Party Loans | 4.7421 billion RMB | 5.1361 billion RMB | | Leverage Ratio | 1.95 | 1.58 | [Use of Proceeds](index=13&type=section&id=%E6%89%80%E5%BE%97%E6%AC%BE%E9%A0%85%E7%94%A8%E9%80%94) Proceeds from 2021 and 2025 placements were largely used for strategic acquisitions, tech service expansion, platform development, and AI R&D - Net proceeds from the 2021 placement, approximately **551 million HKD**, have been substantially utilized for strategic acquisitions, development of supply chain technology services, and general working capital for platformization[41](index=41&type=chunk)[45](index=45&type=chunk) - Net proceeds from the 2025 placement, approximately **209 million HKD**, have been largely used to accelerate platform technology service expansion, focusing on innovative areas like e-commerce, AI applications, and robotics, as well as increasing R&D investment in the 'Shengyitong Cloud Platform'[43](index=43&type=chunk)[45](index=45&type=chunk) [Corporate Governance and Other Information](index=20&type=section&id=%E4%BC%81%E6%A5%AD%E7%AE%A1%E6%B2%BB%E5%8F%8A%E5%85%B6%E4%BB%96%E8%B3%87%E6%96%99) The company complied with corporate governance codes, maintained public float, and the Audit Committee reviewed interim financials - The company complied with the Corporate Governance Code set out in Appendix C1 of the Listing Rules during the reporting period[71](index=71&type=chunk) - The company maintained a public float of no less than **25%**[68](index=68&type=chunk) - The Audit Committee reviewed the Group's unaudited condensed consolidated financial statements for the six months ended June 30, 2025[73](index=73&type=chunk) [Condensed Consolidated Financial Statements](index=24&type=section&id=%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E8%B2%A1%E5%8B%99%E5%A0%B1%E8%A1%A8) This section presents the company's condensed consolidated financial statements: profit or loss, comprehensive income, financial position, equity, and cash flows [Condensed Consolidated Statement of Profit or Loss](index=24&type=section&id=%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E6%90%8D%E7%9B%8A%E8%A1%A8) Despite revenue decrease, profit increased from **165 million RMB to 203 million RMB**, driven by lower financing costs and associate profits [Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=25&type=section&id=%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E6%90%8D%E7%9B%8A%E5%8F%8A%E5%85%B6%E4%BB%96%E5%85%A8%E9%9D%A2%E6%94%B6%E7%9B%8A%E8%A1%A8) Total comprehensive income for the period was **205 million RMB**, higher than **168 million RMB** in the prior year, including other comprehensive income [Condensed Consolidated Statement of Financial Position](index=26&type=section&id=%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E8%B2%A1%E5%8B%99%E7%8B%80%E6%B3%81%E8%A1%A8) Total assets decreased from **10.60 billion RMB** to **10.54 billion RMB**, total liabilities increased from **6.48 billion RMB** to **6.97 billion RMB**, reducing net assets [Condensed Consolidated Statement of Changes in Equity](index=28&type=section&id=%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E6%AC%8A%E7%9B%8A%E8%AE%8A%E5%8B%95%E8%A1%A8) This statement details changes in shareholders' equity components, including profit, dividends, share issuance, and share-based payments [Condensed Consolidated Statement of Cash Flows](index=30&type=section&id=%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E7%8F%BE%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) Net cash inflow from operating activities was **3.56 billion RMB**, with net outflows from investing and financing activities, ending with **713 million RMB** cash [Notes to the Condensed Consolidated Financial Statements](index=32&type=section&id=%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E8%B2%A1%E5%8B%99%E5%A0%B1%E8%A1%A8%E9%99%84%E8%A8%BB) This section provides detailed notes to the condensed consolidated financial statements, explaining key financial figures and accounting policies [Note 4: Operating Revenue and Income](index=33&type=section&id=4.%20%E4%B8%BB%E7%87%9F%E6%A5%AD%E5%8B%99%E6%94%B6%E5%85%A5%E5%8F%8A%E6%94%B6%E7%9B%8A) This note details operating revenue breakdown, with platform inclusive matching and referral services as key components of platform technology service revenue Platform Technology Service Revenue Breakdown (RMB thousands) | Service Type | H1 2025 | H1 2024 | | :--- | :--- | :--- | | Platform Inclusive Matching Technology Services | 97,825 | 100,997 | | Referral Services | 92,577 | 50,913 | | Digital Ecosystem Services | 12,517 | – | | ABS Product Technology Services | 3,561 | 1,038 | | AI Information Services | 427 | – | | Other Services | 3,734 | 831 | | **Total** | **210,641** | **153,779** | [Note 9: Dividends](index=36&type=section&id=9.%20%E8%82%A1%20%E6%81%AF) This note discloses dividends declared, including the 2024 final and 2025 special dividends, totaling approximately **951 million RMB** Dividends Declared During the Period | Dividend Item | Amount (RMB thousands) | | :--- | :--- | | 2024 Final Dividend (RMB 0.347 per share) | 349,504 | | 2025 Special Dividend (RMB 0.596 per share) | 601,149 | | **Total** | **950,653** | [Note 10: Earnings Per Share](index=36&type=section&id=10.%20%E6%AF%8F%E8%82%A1%E7%9B%88%E5%88%A9) This note presents data for basic and diluted EPS calculation, with both basic and diluted EPS at **20 RMB cents** Earnings Per Share Calculation | Indicator | H1 2025 | H1 2024 | | :--- | :--- | :--- | | Profit (RMB thousands) | 199,841 | 155,322 | | Weighted Average Number of Ordinary Shares (thousands) | 980,234 | 979,697 | | Diluted Weighted Average Number of Ordinary Shares (thousands) | 984,071 | 979,957 |
科济药业(02171) - 2025 - 年度业绩
2025-08-14 14:30
Performance Highlights [Financial Highlights](index=1&type=section&id=Financial%20Highlights) For the six months ended June 30, 2025, the company significantly improved its financial position, with revenue of RMB 51 million, gross profit of RMB 29 million, and a narrowed net loss of RMB 75 million, supported by strong cash reserves Key Financial Indicators for the Six Months Ended June 30, 2025 | Metric | H1 2025 (Million RMB) | H1 2024 (Million RMB) | YoY Change | | :--- | :--- | :--- | :--- | | Revenue | Approx. 51 | Approx. 6.3 | +704% | | Gross Profit | Approx. 29 | Approx. 1.6 | +1712% | | Net Loss | Approx. 75 | Approx. 352 | Loss narrowed by 78.7% | | Adjusted Net Loss | Approx. 72 | Approx. 342 | Loss narrowed by 79.0% | | Cash and Bank Balances at Period-End | Approx. 1,261 | - | - | - The significant reduction in net loss was primarily due to: (i) increased net other income; (ii) a **RMB 116 million** decrease in R&D expenses; (iii) a **RMB 47 million** decrease in administrative expenses; and (iv) increased gross profit[5](index=5&type=chunk) - As of June 30, 2025, cash and bank balances were approximately **RMB 1.261 billion**, with existing funds projected to support operations until 2028[7](index=7&type=chunk) [Business Highlights](index=3&type=section&id=Business%20Highlights) The company achieved significant business progress, with successful commercialization of core product CT053, NDA acceptance for CT041, and active advancement of differentiated allogeneic CAR-T pipelines using proprietary platforms - Commercialization of **CT053 (Zevor-cel)** in mainland China, in collaboration with Huadong Medicine, progressed smoothly, securing **111 valid orders** in H1 2025[9](index=9&type=chunk) - The New Drug Application (NDA) for **CT041 (Sure-cel)** for advanced gastric cancer was accepted by China's NMPA, granted priority review, and designated as a breakthrough therapy[10](index=10&type=chunk) - The company is advancing multiple allogeneic CAR-T cell products, including CT0596, using its proprietary THANK-uCAR® and upgraded THANK-u Plus™ platforms to overcome limitations of existing therapies[11](index=11&type=chunk) Business Review and Outlook [Company Overview and Strategy](index=4&type=section&id=Company%20Overview%20and%20Strategy) Coherent Biopharma is a biopharmaceutical company focused on innovative CAR-T cell therapies with end-to-end capabilities, strategically optimizing its pipeline for differentiated clinical and commercial value while expanding into the US market - The company is positioned as a biopharmaceutical firm dedicated to developing innovative CAR-T cell therapies addressing unmet clinical needs in hematological malignancies, solid tumors, and autoimmune diseases[12](index=12&type=chunk) - The company's strategy focuses on developing breakthrough CAR-T products, regularly evaluating its pipeline for differentiated projects, and actively integrating resources to advance its US market strategy[13](index=13&type=chunk) [Product Pipeline Review](index=4&type=section&id=Product%20Pipeline%20Review) The company boasts a rich product pipeline, including commercialized CT053, NDA-accepted CT041, and multiple clinical and preclinical candidates targeting novel antigens and allogeneic CAR-T, demonstrating robust R&D innovation Key Product Pipeline Progress | Candidate Product | Target | Primary Indication | Latest Progress | | :--- | :--- | :--- | :--- | | **Zevor-cel (CT053)** | BCMA | Relapsed/Refractory Multiple Myeloma | Commercialized in China | | **Sure-cel (CT041)** | Claudin18.2 | Gastric Cancer/GEJ Adenocarcinoma | NDA accepted in China | | **CT071** | GPRC5D | Relapsed/Refractory Multiple Myeloma | Phase I clinical, ORR data 100% | | **CT011** | GPC3 | Hepatocellular Carcinoma | NMPA IND approved | | **Allogeneic CAR-T** | BCMA, CD19/20, etc. | Multiple Myeloma, B-cell Lymphoma, etc. | Multiple products in IIT stage, CT0596 showing positive preliminary efficacy | [Zevor-cel (CT053) - BCMA CAR-T](index=5&type=section&id=Zevor-cel%20(CT053)%20-%20BCMA%20CAR-T) Zevor-cel (CT053), an NMPA-approved all-human BCMA CAR-T product, is commercializing well in China with 111 orders in H1 2025 and showed a 92.2% ORR in LUMMICAR-1, though its US/Canada LUMMICAR-2 study priority has been strategically reduced - In collaboration with Huadong Medicine for commercialization in mainland China, Coherent Biopharma is eligible for up to **RMB 1.025 billion** in regulatory and sales milestone payments, having secured **111 valid orders** in H1 2025[17](index=17&type=chunk) - LUMMICAR-1 study data showed an **Overall Response Rate (ORR) of 92.2%** and a **stringent Complete Response (sCR)/Complete Response (CR) rate of 71.6%** in 102 patients[20](index=20&type=chunk) - As part of a strategic adjustment, the company decided to de-prioritize the LUMMICAR-2 study for Zevor-cel in the US and Canada[21](index=21&type=chunk) [Sure-cel (CT041) - Claudin18.2 CAR-T](index=6&type=section&id=Sure-cel%20(CT041)%20-%20Claudin18.2%20CAR-T) Sure-cel (CT041), a potential global first-in-class Claudin18.2 CAR-T, received NMPA NDA acceptance, priority review, and breakthrough therapy designation in June 2025 for advanced gastric/GEJ adenocarcinoma, demonstrating significant PFS/OS improvement and manageable safety in a confirmatory Phase II trial - In June 2025, the NDA for Sure-cel was accepted by China's NMPA for Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma patients who failed at least two prior lines of therapy[23](index=23&type=chunk) - Confirmatory Phase II clinical trial (CT041-ST-01) data showed a **median Overall Survival (mOS) of 9.17 months** for Sure-cel-treated patients, compared to only **3.98 months** for the control group[24](index=24&type=chunk) - The company is actively exploring the product's application in earlier cancer treatment and perioperative settings, including adjuvant therapy for pancreatic cancer and post-gastrectomy consolidation therapy for gastric cancer[25](index=25&type=chunk) [CT011 - GPC3 CAR-T](index=8&type=section&id=CT011%20-%20GPC3%20CAR-T) CT011, an autologous GPC3-targeted CAR-T product for hepatocellular carcinoma (HCC), received NMPA IND approval in January 2024 for adjuvant therapy in GPC3-positive Stage IIIa HCC patients at risk of recurrence post-surgery, building on the founder's pioneering work - CT011 is an autologous GPC3-targeted CAR-T product for the treatment of hepatocellular carcinoma (HCC)[30](index=30&type=chunk) - In January 2024, CT011 received NMPA IND approval for adjuvant therapy in GPC3-positive Stage IIIa HCC patients at risk of recurrence after surgical resection[30](index=30&type=chunk) [CT071 - GPRC5D CAR-T](index=9&type=section&id=CT071%20-%20GPRC5D%20CAR-T) CT071, an autologous GPRC5D-targeted CAR-T developed with the CARcelerate® platform to reduce manufacturing time to 30 hours, demonstrated a **100% ORR** and **70% sCR** in a Phase I investigator-initiated trial for newly diagnosed multiple myeloma, highlighting its significant therapeutic potential - CT071, developed using the proprietary CARcelerate® platform, reduces manufacturing time to approximately **30 hours**, yielding younger and more potent CAR-T cells[32](index=32&type=chunk) - In a Phase I study for high-risk newly diagnosed multiple myeloma, CT071 achieved a **100% Overall Response Rate (ORR)**, with **70% of patients achieving stringent Complete Response (sCR)**[32](index=32&type=chunk) [Allogeneic CAR-T Cell Products](index=9&type=section&id=Allogeneic%20CAR-T%20Cell%20Products) Leveraging its proprietary THANK-uCAR® and upgraded THANK-u Plus™ platforms, the company is aggressively advancing its allogeneic CAR-T pipeline, with BCMA-targeted CT0596 showing encouraging efficacy and safety in R/R MM, and a dedicated subsidiary, Youkai-cel, established for R&D and commercialization of multiple allogeneic products - The company developed the THANK-u Plus™ platform as an upgrade to THANK-uCAR® technology, aiming to overcome the potential impact of NKG2A expression levels on allogeneic CAR-T efficacy[34](index=34&type=chunk) - In a preliminary clinical study of allogeneic product CT0596 for R/R MM, **3 out of 5 (60%)** patients who completed initial efficacy assessment achieved sCR/CR, **4 (80%)** achieved MRD negativity, with good safety[36](index=36&type=chunk) - The company established Youkai-cel, a subsidiary, and secured **RMB 80 million** in external investment, focusing on the R&D, manufacturing, and commercialization of allogeneic CAR-T cell therapies in China[38](index=38&type=chunk) [Technology Platforms and Innovation](index=11&type=section&id=Technology%20Platforms%20and%20Innovation) The company addresses CAR-T challenges through innovative platforms: THANK-uCAR®/THANK-u Plus™ for effective allogeneic CAR-T, CARcelerate® for 30-hour manufacturing, and CycloCAR®/LADAR™ for enhanced solid tumor efficacy and improved target availability/safety, holding over 300 patents Core Technology Platforms | Technology Platform | Goals and Advantages | | :--- | :--- | | **THANK-uCAR® / THANK-u Plus™** | Develop allogeneic CAR-T, improve patient accessibility, enhance cell expansion and persistence | | **CARcelerate®** | Reduce CAR-T cell manufacturing time to approximately 30 hours, improving production efficiency and cell potency | | **CycloCAR®** | Co-express IL-7 and CCL21, enhance efficacy against solid tumors, reduce lymphodepletion requirements | | **LADAR™** | Precisely control CAR-T cell activation through dual-antigen recognition, enhance safety, and address target availability challenges | - As of June 30, 2025, the company holds over **300 patents**, including **140 globally authorized patents**, demonstrating a robust intellectual property portfolio[44](index=44&type=chunk) [Manufacturing Capabilities](index=14&type=section&id=Manufacturing%20Capabilities) The company has established vertically integrated GMP manufacturing capabilities for plasmids, lentiviral vectors, and CAR-T cell products, supporting clinical trials and commercialization, with its Shanghai Jinshan plant serving China and the US RTP facility cleared by FDA for overseas clinical trials - The company has established vertically integrated CAR-T manufacturing capabilities, encompassing plasmids, lentiviral vectors, and CAR-T cell products, enhancing efficiency, control, and cost reduction[46](index=46&type=chunk) - The Shanghai Jinshan facility supports the commercial production of Zevor-cel and prepares for the commercialization of Sure-cel[46](index=46&type=chunk) - The RTP manufacturing facility in North Carolina, USA, passed an FDA re-inspection with zero deficiencies in September 2024, leading to the lifting of clinical hold on three trials by the FDA in October of the same year[47](index=47&type=chunk) [Market Outlook and Future Prospects](index=15&type=section&id=Market%20Outlook%20and%20Future%20Prospects) The global CAR-T market shows strong growth, with significant unmet needs in solid tumors; the company aims to advance core products into earlier treatment, develop innovative technologies, expand manufacturing, and seek collaborations to maximize value - The global CAR-T market is experiencing strong growth, yet significant unmet needs persist in solid tumor treatment, presenting development opportunities for the company[48](index=48&type=chunk) - The company's future focus includes: 1) advancing core products into earlier treatment; 2) developing other clinical and preclinical products; 3) continuously innovating CAR-T technologies; 4) expanding US and China manufacturing capabilities; and 5) establishing more external collaborations[49](index=49&type=chunk) Financial Review [Operating Performance Analysis](index=16&type=section&id=Operating%20Performance%20Analysis) During the reporting period, the company's operating loss significantly narrowed from RMB 362 million to RMB 77 million, with net loss decreasing by RMB 277 million to RMB 75 million, primarily due to controlled expenses, increased foreign exchange gains, and higher gross profit Operating Loss and Net Loss | Metric | H1 2025 (Million RMB) | H1 2024 (Million RMB) | | :--- | :--- | :--- | | Operating Loss | 77 | 362 | | Net Loss | 75 | 352 | - The reduction in loss was primarily attributed to decreased R&D expenses, reduced administrative expenses, increased net foreign exchange gains, and higher gross profit[51](index=51&type=chunk) [Non-IFRS Measures](index=16&type=section&id=Non-IFRS%20Measures) To better assess core business performance, the company reported Non-IFRS measures, with adjusted net loss for the six months ended June 30, 2025, significantly narrowing to RMB 71.8 million from RMB 342 million after excluding non-cash items like share-based compensation Reconciliation of Net Loss to Adjusted Net Loss (RMB Thousand) | Item | H1 2025 (Unaudited) | H1 2024 (Unaudited) | | :--- | :--- | :--- | | Loss for the period | (75,483) | (351,558) | | Add: Share-based payment expenses | 3,684 | 9,190 | | **Adjusted Net Loss** | **(71,799)** | **(342,368)** | [Analysis of Key Financial Items](index=17&type=section&id=Analysis%20of%20Key%20Financial%20Items) During the period, the company effectively controlled expenses, with revenue growing over 7-fold to RMB 50.96 million, R&D expenses decreasing by **47%** to RMB 130 million, and administrative expenses by **54%** to RMB 39 million, primarily due to lower staff costs, professional fees, and depreciation - R&D expenses decreased by **47%** from **RMB 246 million** to **RMB 130 million**, primarily due to reduced employee benefit expenses, testing and clinical expenses, and depreciation of property, plant, and equipment[58](index=58&type=chunk) - Administrative expenses decreased by **54%** from **RMB 86 million** to **RMB 39 million**, mainly due to reduced employee benefit expenses, professional service fees, and depreciation of property, plant, and equipment[59](index=59&type=chunk)[60](index=60&type=chunk) - Total employee benefit expenses decreased from **RMB 154 million** to **RMB 89.79 million**, primarily due to a reduction in headcount and lower remuneration[60](index=60&type=chunk) [Liquidity and Capital Resources](index=20&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2025, the company held RMB 1.261 billion in cash and bank balances, with improved net cash outflow from operating activities of RMB 196 million and a net outflow of RMB 30 million from financing activities, resulting in zero total borrowings and a reduced liability ratio of **7.2%**, indicating a more robust financial structure Condensed Cash Flow Statement (RMB Thousand) | Item | H1 2025 (Unaudited) | H1 2024 (Unaudited) | | :--- | :--- | :--- | | Net cash used in operating activities | (196,308) | (255,947) | | Net cash generated from investing activities | 1,715 | 6,584 | | Net cash (used in)/generated from financing activities | (29,635) | 24,688 | | **Cash and cash equivalents at period-end** | **1,260,793** | **1,652,569** | - As of June 30, 2025, the Group's total borrowings decreased to **zero**, and the liability ratio (sum of borrowings and lease liabilities/total equity) decreased from **15.75%** at the end of 2024 to **7.2%**[69](index=69&type=chunk) - As of June 30, 2025, the company's total headcount was **371**, a reduction from **468** at the end of 2024[78](index=78&type=chunk) Supplemental Announcement Regarding 2024 Annual Report [Impairment Background and Reasons](index=24&type=section&id=Impairment%20Background%20and%20Reasons) This supplemental announcement clarifies asset impairments in the 2024 annual report, stemming from a strategic shift to allogeneic CAR-T pipelines due to strong data and competitive changes, reallocating resources from certain autologous pipelines lacking clear commercialization plans - For the year ended December 31, 2024, the company recorded an impairment of **RMB 162.3 million** for property, plant, and equipment, **RMB 26.5 million** for right-of-use assets, and **RMB 0.3 million** for intangible assets[81](index=81&type=chunk) - The primary reason for impairment was a strategic shift: due to excellent allogeneic CAR-T data, the company decided to reallocate resources from certain autologous CAR-T pipelines to allogeneic pipelines[82](index=82&type=chunk)[83](index=83&type=chunk) [Key Assumptions and Impairment Testing](index=24&type=section&id=Key%20Assumptions%20and%20Impairment%20Testing) The company conducted impairment tests on long-term assets based on strategic adjustments, using the Value in Use (VIU) method for autologous pipeline assets without clear commercialization plans, and fully impairing assets solely dedicated to these pipelines due to zero expected future cash inflows - Key impairment testing assumptions included reduced resource allocation to autologous pipelines without clear commercialization plans, and no definite commercialization plans for other autologous pipelines beyond those already marketed or in NDA stage[83](index=83&type=chunk) - The company used the Value in Use (VIU) method for impairment testing, with assets solely dedicated to de-prioritized autologous pipelines assigned a **zero VIU**, leading to a full impairment provision[84](index=84&type=chunk)[85](index=85&type=chunk) Condensed Consolidated Financial Statements [Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=26&type=section&id=Consolidated%20Statement%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income) For the six months ended June 30, 2025, the company reported a gross profit of RMB 29.37 million, a significantly narrowed operating loss of RMB 76.70 million from RMB 362 million, and a net loss of RMB 75.48 million, representing a **78.5%** year-over-year reduction, with basic loss per share at **RMB 0.14** Condensed Interim Consolidated Statement of Profit or Loss Summary (RMB Thousand) | Item | H1 2025 (Unaudited) | H1 2024 (Unaudited) | | :--- | :--- | :--- | | Revenue | 50,961 | 6,340 | | Gross Profit | 29,369 | 1,617 | | Operating Loss | (76,704) | (361,540) | | Loss before income tax | (75,483) | (351,558) | | **Loss for the period attributable to owners of the parent** | **(75,483)** | **(351,558)** | | Basic and diluted loss per share (RMB) | (0.14) | (0.63) | [Consolidated Statement of Financial Position](index=27&type=section&id=Consolidated%20Statement%20of%20Financial%20Position) As of June 30, 2025, the company reported total assets of RMB 1.513 billion, total liabilities of RMB 551 million, and net assets of RMB 962 million, with strong liquidity from RMB 1.380 billion in current assets, including RMB 1.261 billion in cash and bank balances, and an optimized balance sheet with zero interest-bearing bank borrowings Condensed Interim Consolidated Statement of Financial Position Summary (RMB Thousand) | Item | As of June 30, 2025 (Unaudited) | As of December 31, 2024 (Audited) | | :--- | :--- | :--- | | Total non-current assets | 133,498 | 142,759 | | Total current assets | 1,379,893 | 1,530,275 | | **Total Assets** | **1,513,391** | **1,673,034** | | Total current liabilities | 213,799 | 254,007 | | Total non-current liabilities | 337,459 | 362,320 | | **Total Liabilities** | **551,258** | **616,327** | | **Net Assets** | **962,133** | **1,056,707** | | Total Equity | 962,133 | 1,056,707 | Corporate Governance and Other Information [Dividends and Securities Transactions](index=36&type=section&id=Dividends%20and%20Securities%20Transactions) The Board recommends no interim dividend for the six months ended June 30, 2025, with no purchases, sales, or redemptions of listed securities by the company or its subsidiaries during the period, and all directors confirmed compliance with the adopted standard code - The Board recommends no interim dividend for the reporting period[116](index=116&type=chunk) - During the reporting period, neither the company nor its subsidiaries acquired, disposed of, or redeemed any of the company's listed securities[117](index=117&type=chunk) [Use of Proceeds from Global Offering](index=37&type=section&id=Use%20of%20Proceeds%20from%20Global%20Offering) The company, listed in June 2021, utilized approximately RMB 2.497 billion of its HKD 3.008 billion net global offering proceeds by June 30, 2025, primarily for CT053 development, pipeline R&D, and manufacturing, with the remaining balance expected to be fully used by 2026 Use of Proceeds from Global Offering (As of June 30, 2025) | Use of Proceeds | Planned Allocation (Million RMB) | Amount Utilized (Million RMB) | Balance (Million RMB) | | :--- | :--- | :--- | :--- | | Development of core product BCMA CAR-T (CT053) | 851.7 | 851.7 | 0 | | R&D for other pipelines | 849.9 | 759.6 | 90.3 | | Manufacturing and commercialization capabilities | 548.3 | 415.2 | 133.1 | | Technology upgrades and early-stage R&D | 274.1 | 214.7 | 59.4 | | Working capital and others | 255.5 | 255.5 | 0 | | **Total** | **2,779.5** | **2,496.7** | **282.8** | - The unutilized portion of the net proceeds is expected to be fully used for its intended purposes by 2026[124](index=124&type=chunk)
TL NATURAL GAS(08536) - 2025 - 中期业绩
2025-08-14 14:23
(於 開 曼 群 島 註 冊 成 立 的 有 限 公 司) (股 份 代 號:8536) 截至二零二五年六月三十日止六個月之 中期業績公告 TL Natural Gas Holdings Limited(「本公司」,連 同 其 附 屬 公 司 為「本集團」)董 事(「董 事」)會(「董事會」)欣然宣佈本集團截至二零二五年六月三十日止六個月之中期 未 經 審 核 綜 合 業 績。本 公 告 載 有 本 公 司 二 零 二 五 年 中 期 報 告(「二零二五年中 期報告」)全 文,符 合 香 港 聯 合 交 易 所 有 限 公 司GEM證券上市規則(「GEM上市規 則」)有 關 中 期 業 績 初 步 公 告 隨 附 資 料 之 相 關 規 定。二 零 二 五 年 中 期 報 告 的 印 刷 版 本 將 於 適 當 時 候 寄 發 予 本 公 司 的 股 東,並 刊 登 在 香 港 聯 合 交 易 所 有 限 公 司 網 站 www.hkexnews.hk 及本公司網站 www.tl-cng.com 以 供 閱 覽。 承董事會命 TL Natural Gas Holdings Limited 執 行 董 事、主 ...
吉林长龙药业(08049) - 2025 - 中期财报
2025-08-14 13:17
2025 2025 香港聯合交易所有限公司(「聯交所」)GEM的特色 GEM的定位乃為相比其他在聯交所上市的公司可能帶有較高投資風險的中小型公司提供一個上 市的市場。有意投資者應了解投資於該等公司的潛在風險,並應經過審慎周詳的考慮後方作出投 資決定。 由於GEM上市公司一般為中小型公司,在GEM買賣的證券可能會較於聯交所主板買賣的證券承 受較大的市場波動風險,同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及香港聯合交易所有限公司對本報告的內容概不負責,對其準確性或 完整性亦不發表任何聲明,並明確表示概不會就因本報告全部或部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本報告(吉林省輝南長龍生化藥業股份有限公司的董事(「董事」)願共同及個別對此負全責)乃遵照 GEM證券上市規則(「GEM上市規則」)的規定而提供有關吉林省輝南長龍生化藥業股份有限公司 及其附屬公司(「本集團」)的資料。董事經作出一切合理查詢後,確認就彼等所知及所信:(1)本 報告所載資料在各重大方面均屬準確及完整,且無誤導成份;(2)並無遺漏任何事實致使本報告 所載任何聲明產生誤導;及(3)本報告內表 ...
吉林长龙药业(08049) - 2025 - 中期业绩
2025-08-14 13:14
Jilin Province Huinan Changlong Bio-pharmacy Company Limited (於中華人民共和國註冊成立之股份有限公司) (股份代號:8049) 中期業績公告 截至二零二五年六月三十日止六個月 香 港 聯 合 交 易 所 有 限 公 司(「聯 交 所」)GEM的特色 GEM的定位乃為相比其他在聯交所上市的公司可能帶有較高投資風險的中小 型 公 司 提 供 一 個 上 市 的 市 場。有 意 投 資 者 應 了 解 投 資 於 該 等 公 司 的 潛 在 風 險, 並 應 經 過 審 慎 周 詳 的 考 慮 後 方 作 出 投 資 決 定。 由 於GEM上 市 公 司 一 般 為 中 小 型 公 司,在GEM買賣的證券可能會較於聯交所 主 板 買 賣 的 證 券 承 受 較 大 的 市 場 波 動 風 險,同 時 無 法 保 證 在GEM買賣的證券 會 有 高 流 通 量 的 市 場。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責,對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明,並 明 確 表 示 概 不 會 就 因 ...
吉星新能源(03395) - 2025 - 中期业绩
2025-08-14 13:06
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責,對其準確 性或完整性亦不發表任何聲明,並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 JX Energy Ltd. (吉星新能源有限責任公司)* ( 根據阿爾伯塔法例註冊成立的有限責任公司) (股份代號:3395) 截至2025年6月30日止三個月及六個月之未經審核業績公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.49(6)條刊發。 吉星新能源有限責任公司*董事會欣然公佈截至2025年6月30日止三個月及六個月之未經 審核簡明中期財務業績。 吉星新能源有限責任公司(「本公司」)董事會(「董事會」)欣然公佈本公司截至2025年6月30 日止三個月及六個月的未經審核簡明中期財務業績(「中期業績」)。本公司根據香港聯合交易 所有限公司證券上市規則(「上市規則」)第13.49(6)條刊發本公告。董事會及其審核及風險委 員會已審閱中期業績。詳情請參閱隨附的公告。 承董事會命 吉星新能源有限責任公司* 主席兼臨時首席執行官 柳永坦 卡加利,2025年8月13日 香港,2025年8月14日 ...
盛龙锦秀国际(08481) - 2025 - 中期业绩
2025-08-14 12:56
香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司(「聯交所」)對 本 公 告 的 內 容 概 不 負 責,對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明,並 明 確 表 示,概 不 就因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失 承 擔 任 何 責 任。 SHENGLONG SPLENDECOR INTERNATIONAL LIMITED 盛龍錦秀國際有限公司 (於開曼群島註冊成立的有限公司) (股份代號:8481) 截至二零二五年六月三十日止六個月之 中期業績公告 盛 龍 錦 秀 國 際 有 限 公 司(「本公司」連 同 其 附 屬 公 司,為「本集團」)之 董 事(「董 事」) 會(「董事會」)欣 然 宣 佈 本 集 團 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月 之 未 經 審 核 簡 明 綜 合 業 績。本 公 告 載 有 本 公 司 二 零 二 五 年 中 期 報 告 全 文,符 合 聯 交 所GEM 證 券 上 市 規 則(「GEM上市規則」)有 關 中 期 業 績 初 步 公 告 之 資 料 ...
新利软件(08076) - 2025 - 中期业绩
2025-08-14 12:54
(於百慕達註冊成立的有限公司) (股份代號:8076) 截至二零二五年六月三十日止六個月的 中期業績公佈 香港聯合交易所有限公司(「聯交所」)GEM之特色 GEM的定位,乃為中小型公司提供一個上市的市場,此等公司相比起其他在主板上市的公司 帶有較高投資風險。有意投資的人士應了解投資於該等公司的潛在風險,並經過審慎周詳考 慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司,在GEM買賣的證券可能會較於主板買賣的證券承受 更大的市場波動風險,同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責,對其準確 性或完整性亦不發表任何聲明,並明確表示概不就因本公佈全部或任何部份內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 本公佈乃遵照香港聯合交易所有限公司的GEM證券上市規則之規定而提供有關新利軟件(集 團)股份有限公司(「本公司」)之資料。本公司各董事(「董事」)願就本公佈所載內容共同及 個別承擔全部責任。董事在作出一切合理查詢後,確認就彼等所知及所信:本公佈所載資料 在各重大方面均屬準確及完整,且無誤導或欺詐成份;本公佈並無遺漏 ...
基石药业(02616) - 2025 - 中期业绩
2025-08-14 11:02
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其準確性 或完整性亦不發表任何聲明,並明確表示,概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CStone Pharmaceuticals 基石藥業 (於開曼群島註冊成立的有限公司) (股份代號:2616) 截至二零二五年六月三十日止六個月中期業績公告 基石藥業(「本公司」或「基石藥業」)董事(「董事」)會(「董事會」)欣然宣佈,本公 司及其附屬公司(統稱「本集團」或「我們」)截至二零二五年六月三十日止六個月 (「報告期間」)的未經審核簡明綜合業績,連同截至二零二四年六月三十日止六個 月的比較數字。除文義另有所指外,本公告所用詞彙與本公司日期為二零一九年 二月十四日的招股章程(「招股章程」)以及日期為二零二四年八月二十三日的截至 二零二四年六月三十日止六個月之中期業績公告所界定者具有相同涵義。 財務摘要 國際財務報告準則(「國際財務報告準則」)計量: 1 • 收入由截至二零二四年六月三十日止六個月的人民幣254.2百萬元減少人民幣 204.8百萬元或80.5%至截至二零二五年六月三十日止六個月的 ...